We have an Exclusive Channel Collaboration (ECC) agreement with Intrexon. This agreement provides for our worldwide exclusive use of Intrexon’s proprietary synthetic biology technology platform for the development and commercialization of genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. The focus of the collaboration activities to date has been on the identification and production of an off-the-shelf, allogeneic chondrocyte cell line that can be used to develop a next generation, allogeneic NeoCart. The collaboration has produced compelling, proof-of-concept data showing NeoCart implants based on iPSC derived chondrocytes that exhibited similar properties to current generation, autologous NeoCart tissue implants. The parties are now working to define the development and regulatory pathway for this potential product.
View more about Intrexon on their website.
If you are interesting in partnering opportunities with Histogenics, please email us at InvestorRelations@histogenics.com